NCT03591510 2026-03-13
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Novartis
Phase 2 Active not recruiting
Novartis
Kura Oncology, Inc.
Janssen Research & Development, LLC
Incyte Corporation
Sichuan Baili Pharmaceutical Co., Ltd.
Genmab
Daiichi Sankyo